Efficacy and safety of PD-L1 inhibitors versus PD-1 inhibitors in first-line treatment with chemotherapy for extensive-stage small-cell lung cancer

[1] Oronsky B(2017)What's new in SCLC? a review Neoplasia (New York, NY) 19 842-847

[2] Reid T(2007)Small cell lung cancer: have we made any progress over the last 25 years? Oncologist 12 1096-1104

[3] Oronsky A(2011)1st ESMO consensus conference in lung cancer; lugano 2010: small-cell lung cancer Ann Oncol: Off J Eur Soc Med Oncol 22 1973-1980

[4] Carter C(2013)Small-cell lung cancer (SCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up Ann Oncol : Off J Eur Soc Med Oncol 24 vi99-vi105

[5] Lally B(2018)NCCN guidelines insights: small cell lung cancer, version 2.2018 J Natl Compr Cancer Netw : JNCCN 16 1171-1182

[6] Urbanic J(2018)Current standards for clinical management of small cell lung cancer Transl Lung Cancer Res 7 69-79

[7] Blackstock A(2021)Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133) J Clin Oncol : Off J Am Soc Clin Oncol 39 619-630

[8] Miller A(2019)Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial Lancet (London, England) 394 1929-1939

[9] Perry M(2018)Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer N Engl J Med 378 2078-2092

[10] Stahel R(2016)Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study Lancet Oncol 17 1497-1508

[1] Oronsky B(2017)What's new in SCLC? a review Neoplasia (New York, NY) 19 842-847

[2] Reid T(2007)Small cell lung cancer: have we made any progress over the last 25 years? Oncologist 12 1096-1104

[3] Oronsky A(2011)1st ESMO consensus conference in lung cancer; lugano 2010: small-cell lung cancer Ann Oncol: Off J Eur Soc Med Oncol 22 1973-1980

[4] Carter C(2013)Small-cell lung cancer (SCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up Ann Oncol : Off J Eur Soc Med Oncol 24 vi99-vi105

[5] Lally B(2018)NCCN guidelines insights: small cell lung cancer, version 2.2018 J Natl Compr Cancer Netw : JNCCN 16 1171-1182

[6] Urbanic J(2018)Current standards for clinical management of small cell lung cancer Transl Lung Cancer Res 7 69-79

[7] Blackstock A(2021)Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133) J Clin Oncol : Off J Am Soc Clin Oncol 39 619-630

[8] Miller A(2019)Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial Lancet (London, England) 394 1929-1939

[9] Perry M(2018)Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer N Engl J Med 378 2078-2092

[10] Stahel R(2016)Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study Lancet Oncol 17 1497-1508